Neuroblastoma and medulloblastoma are common neuroectodermal tumors (NETs) of childhood. The tumor cells usually have molecular features of neuroblasts. Most neuroblastomas and a third of medulloblastomas express plasma membrane nerve growth factor (NGF) receptors (NGFR). Only a minority of NGFR + NET lines differentiate with NGF treatment, though NGF induces c-fos in many more. Recent studies indicate that c-fos is only one of a family of NGF-inducible transcription factors, and that a coordinated nuclear response to NGF, involving all these gene products, is required to initiate the changes in gene expression required for neuronal differentiation. Using model neuronal cell lines, we have shown that perturbation of any component of this immediate-early gene cascade can block NGF-induced differentiation. Based on these observations, we hypothesize that some human NETs arise because the immediate-early gene response to NGF in the tumor cells is incompetent to transactivate genes required for neuronal differentiation. To test this hypothesis, we plan a comprehensive analysis of the role of the Fos-Jun and Egr family of transcriptional factors in NGF-induced differentiation of human NET responses to NGF. These studies should permit a novel classification scheme for human NETs based on pathogenetic mechanisms, and may suggest avenues for improved therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA047983-04
Application #
3807953
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
4
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Moshier, J A; Skunca, M; Wu, W et al. (1996) Regulation of ornithine decarboxylase gene expression by the Wilms' tumor suppressor WT1. Nucleic Acids Res 24:1149-57
Fredericks, W J; Galili, N; Mukhopadhyay, S et al. (1995) The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol 15:1522-35
Amin, K M; Litzky, L A; Smythe, W R et al. (1995) Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 146:344-56
Werner, H; Shen-Orr, Z; Rauscher 3rd, F J et al. (1995) Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. Mol Cell Biol 15:3516-22
Hol, F A; Hamel, B C; Geurds, M P et al. (1995) A frameshift mutation in the gene for PAX3 in a girl with spina bifida and mild signs of Waardenburg syndrome. J Med Genet 32:52-6
Macina, R A; Barr, F G; Galili, N et al. (1995) Genomic organization of the human PAX3 gene: DNA sequence analysis of the region disrupted in alveolar rhabdomyosarcoma. Genomics 26:1-8
Ryan, G; Steele-Perkins, V; Morris, J F et al. (1995) Repression of Pax-2 by WT1 during normal kidney development. Development 121:867-75
Morris, J F; Rauscher 3rd, F J; Davis, B et al. (1995) The myeloid zinc finger gene, MZF-1, regulates the CD34 promoter in vitro. Blood 86:3640-7
Barr, F G; Chatten, J; D'Cruz, C M et al. (1995) Molecular assays for chromosomal translocations in the diagnosis of pediatric soft tissue sarcomas. JAMA 273:553-7
Bennicelli, J L; Fredericks, W J; Wilson, R B et al. (1995) Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. Oncogene 11:119-30

Showing the most recent 10 out of 75 publications